Supplementary Figure S5 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies by Di Kang (21364656)

Supplementary Figure S4 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Supplementary Figure S8 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Supplementary Figure S1 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Supplementary Figure S2 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Supplementary Figure S7 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Supplementary Figure S6 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Supplementary Figure S3 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Supplementary Figure S5 from Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer by Jacob M. Smigiel (15082077)

Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer by Jia He (89641)

“…Triple-negative breast cancer (TNBC) is a leading malignancy among women that currently lack effective targeted therapeutic agents, and the limitations of treatment have prompted the emergence of new strategies. …”

Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma by Kevin J. Hamblett (2670067)

Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma by Kevin J. Hamblett (2670067)

Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma by Kevin J. Hamblett (2670067)

Supplementary Table S3 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile by Li-Min Wang (22548253)

Supplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile by Li-Min Wang (22548253)

Supplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile by Li-Min Wang (22548253)

Supplementary Table S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile by Li-Min Wang (22548253)

Supplementary Figure S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile by Li-Min Wang (22548253)

Supplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile by Li-Min Wang (22548253)

Supplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile by Li-Min Wang (22548253)